Loading…
Changing paradigms in dermatology: topical immunomodulators within a permutational paradigm for the treatment of atopic and eczematous dermatitis
The first formulation of a class of products called topical immuno modulator s (TIMS) was approved for clinical use in December 2000 and released in February 2001. This product is tacrolimus in an ointment base, prescribed under the trademark Protopic™. The next TIM, pimecrolimus cream, was FDA appr...
Saved in:
| Published in: | Clinics in dermatology 2003-09, Vol.21 (5), p.383-391 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c472t-b1be8dfd33e3eed5e1acf81d289943a80d3780a8a1b283d0aea8a0c97d0728db3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c472t-b1be8dfd33e3eed5e1acf81d289943a80d3780a8a1b283d0aea8a0c97d0728db3 |
| container_end_page | 391 |
| container_issue | 5 |
| container_start_page | 383 |
| container_title | Clinics in dermatology |
| container_volume | 21 |
| creator | Abramovits, William Goldstein, Adrian M. Stevenson, Lisa C. |
| description | The first formulation of a class of products called
topical
immuno
modulator
s (TIMS) was approved for clinical use in December 2000 and released in February 2001. This product is tacrolimus in an ointment base, prescribed under the trademark Protopic™. The next TIM, pimecrolimus cream, was FDA approved in December 2001 and launched February 2002 in a cream vehicle under the trademark Elidel®. TIMs are becoming a significant component in the topical treatment paradigm for atopic dermatitis, introducing a useful alternative to, or complement for, high- and low-potency topical steroid therapy. |
| doi_str_mv | 10.1016/j.clindermatol.2003.08.013 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71469902</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0738081X03000749</els_id><sourcerecordid>71469902</sourcerecordid><originalsourceid>FETCH-LOGICAL-c472t-b1be8dfd33e3eed5e1acf81d289943a80d3780a8a1b283d0aea8a0c97d0728db3</originalsourceid><addsrcrecordid>eNqNkU-P0zAQxS0EYkvhKyALCW4N4zhtnL2h8ldaiQtI3KyJPWldJXaxHdDyLfjGuLSr5cjJI_k3743eY-yFgEqA2Lw-VGZ03lKcMIexqgFkBaoCIR-whVBttxJCiodsAa1UK1Di2xV7ktIBABrYwGN2JZpNq1qhFuz3do9-5_yOHzGidbspcef5nXjY3V7zHI7O4MjdNM0-TMHOY_mLif90eV9g5MeCzxmzC75wd0p8CJHnPfEcCfNEPvMwcPwrx9FbTuYXnWzmdDF02aWn7NGAY6Jnl3fJvr5_92X7cXXz-cOn7ZublWnaOq960ZOyg5WSJJFdk0AzKGFr1XWNRAVWtgpQoehrJS0glRlM11poa2V7uWSvzrrHGL7PlLKeXDI0juipXKTbElLXQV3A6zNoYkgp0qCP0U0Yb7UAfSpEH_S_hehTIRqULoWU5ecXl7mfyN6vXhoowMsLgKmEPET0xqV7bt0063UpcsnenjkqmfxwFHUyjrwh6yKZrG1w_3PPH0HdtfQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71469902</pqid></control><display><type>article</type><title>Changing paradigms in dermatology: topical immunomodulators within a permutational paradigm for the treatment of atopic and eczematous dermatitis</title><source>Elsevier</source><creator>Abramovits, William ; Goldstein, Adrian M. ; Stevenson, Lisa C.</creator><creatorcontrib>Abramovits, William ; Goldstein, Adrian M. ; Stevenson, Lisa C.</creatorcontrib><description>The first formulation of a class of products called
topical
immuno
modulator
s (TIMS) was approved for clinical use in December 2000 and released in February 2001. This product is tacrolimus in an ointment base, prescribed under the trademark Protopic™. The next TIM, pimecrolimus cream, was FDA approved in December 2001 and launched February 2002 in a cream vehicle under the trademark Elidel®. TIMs are becoming a significant component in the topical treatment paradigm for atopic dermatitis, introducing a useful alternative to, or complement for, high- and low-potency topical steroid therapy.</description><identifier>ISSN: 0738-081X</identifier><identifier>EISSN: 1879-1131</identifier><identifier>DOI: 10.1016/j.clindermatol.2003.08.013</identifier><identifier>PMID: 14678718</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adjuvants, Immunologic - administration & dosage ; Administration, Topical ; Allergic diseases ; Biological and medical sciences ; Dermatitis, Atopic - drug therapy ; Dermatitis, Atopic - immunology ; Dermatology ; Dermatology - methods ; Dermatology - trends ; Eczema - drug therapy ; Eczema - immunology ; Humans ; Immunopathology ; Medical sciences ; Skin allergic diseases. Stinging insect allergies</subject><ispartof>Clinics in dermatology, 2003-09, Vol.21 (5), p.383-391</ispartof><rights>2003 Elsevier Inc.</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c472t-b1be8dfd33e3eed5e1acf81d289943a80d3780a8a1b283d0aea8a0c97d0728db3</citedby><cites>FETCH-LOGICAL-c472t-b1be8dfd33e3eed5e1acf81d289943a80d3780a8a1b283d0aea8a0c97d0728db3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15445507$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14678718$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abramovits, William</creatorcontrib><creatorcontrib>Goldstein, Adrian M.</creatorcontrib><creatorcontrib>Stevenson, Lisa C.</creatorcontrib><title>Changing paradigms in dermatology: topical immunomodulators within a permutational paradigm for the treatment of atopic and eczematous dermatitis</title><title>Clinics in dermatology</title><addtitle>Clin Dermatol</addtitle><description>The first formulation of a class of products called
topical
immuno
modulator
s (TIMS) was approved for clinical use in December 2000 and released in February 2001. This product is tacrolimus in an ointment base, prescribed under the trademark Protopic™. The next TIM, pimecrolimus cream, was FDA approved in December 2001 and launched February 2002 in a cream vehicle under the trademark Elidel®. TIMs are becoming a significant component in the topical treatment paradigm for atopic dermatitis, introducing a useful alternative to, or complement for, high- and low-potency topical steroid therapy.</description><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Administration, Topical</subject><subject>Allergic diseases</subject><subject>Biological and medical sciences</subject><subject>Dermatitis, Atopic - drug therapy</subject><subject>Dermatitis, Atopic - immunology</subject><subject>Dermatology</subject><subject>Dermatology - methods</subject><subject>Dermatology - trends</subject><subject>Eczema - drug therapy</subject><subject>Eczema - immunology</subject><subject>Humans</subject><subject>Immunopathology</subject><subject>Medical sciences</subject><subject>Skin allergic diseases. Stinging insect allergies</subject><issn>0738-081X</issn><issn>1879-1131</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqNkU-P0zAQxS0EYkvhKyALCW4N4zhtnL2h8ldaiQtI3KyJPWldJXaxHdDyLfjGuLSr5cjJI_k3743eY-yFgEqA2Lw-VGZ03lKcMIexqgFkBaoCIR-whVBttxJCiodsAa1UK1Di2xV7ktIBABrYwGN2JZpNq1qhFuz3do9-5_yOHzGidbspcef5nXjY3V7zHI7O4MjdNM0-TMHOY_mLif90eV9g5MeCzxmzC75wd0p8CJHnPfEcCfNEPvMwcPwrx9FbTuYXnWzmdDF02aWn7NGAY6Jnl3fJvr5_92X7cXXz-cOn7ZublWnaOq960ZOyg5WSJJFdk0AzKGFr1XWNRAVWtgpQoehrJS0glRlM11poa2V7uWSvzrrHGL7PlLKeXDI0juipXKTbElLXQV3A6zNoYkgp0qCP0U0Yb7UAfSpEH_S_hehTIRqULoWU5ecXl7mfyN6vXhoowMsLgKmEPET0xqV7bt0063UpcsnenjkqmfxwFHUyjrwh6yKZrG1w_3PPH0HdtfQ</recordid><startdate>20030901</startdate><enddate>20030901</enddate><creator>Abramovits, William</creator><creator>Goldstein, Adrian M.</creator><creator>Stevenson, Lisa C.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030901</creationdate><title>Changing paradigms in dermatology: topical immunomodulators within a permutational paradigm for the treatment of atopic and eczematous dermatitis</title><author>Abramovits, William ; Goldstein, Adrian M. ; Stevenson, Lisa C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c472t-b1be8dfd33e3eed5e1acf81d289943a80d3780a8a1b283d0aea8a0c97d0728db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Administration, Topical</topic><topic>Allergic diseases</topic><topic>Biological and medical sciences</topic><topic>Dermatitis, Atopic - drug therapy</topic><topic>Dermatitis, Atopic - immunology</topic><topic>Dermatology</topic><topic>Dermatology - methods</topic><topic>Dermatology - trends</topic><topic>Eczema - drug therapy</topic><topic>Eczema - immunology</topic><topic>Humans</topic><topic>Immunopathology</topic><topic>Medical sciences</topic><topic>Skin allergic diseases. Stinging insect allergies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abramovits, William</creatorcontrib><creatorcontrib>Goldstein, Adrian M.</creatorcontrib><creatorcontrib>Stevenson, Lisa C.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinics in dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abramovits, William</au><au>Goldstein, Adrian M.</au><au>Stevenson, Lisa C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changing paradigms in dermatology: topical immunomodulators within a permutational paradigm for the treatment of atopic and eczematous dermatitis</atitle><jtitle>Clinics in dermatology</jtitle><addtitle>Clin Dermatol</addtitle><date>2003-09-01</date><risdate>2003</risdate><volume>21</volume><issue>5</issue><spage>383</spage><epage>391</epage><pages>383-391</pages><issn>0738-081X</issn><eissn>1879-1131</eissn><abstract>The first formulation of a class of products called
topical
immuno
modulator
s (TIMS) was approved for clinical use in December 2000 and released in February 2001. This product is tacrolimus in an ointment base, prescribed under the trademark Protopic™. The next TIM, pimecrolimus cream, was FDA approved in December 2001 and launched February 2002 in a cream vehicle under the trademark Elidel®. TIMs are becoming a significant component in the topical treatment paradigm for atopic dermatitis, introducing a useful alternative to, or complement for, high- and low-potency topical steroid therapy.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>14678718</pmid><doi>10.1016/j.clindermatol.2003.08.013</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0738-081X |
| ispartof | Clinics in dermatology, 2003-09, Vol.21 (5), p.383-391 |
| issn | 0738-081X 1879-1131 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71469902 |
| source | Elsevier |
| subjects | Adjuvants, Immunologic - administration & dosage Administration, Topical Allergic diseases Biological and medical sciences Dermatitis, Atopic - drug therapy Dermatitis, Atopic - immunology Dermatology Dermatology - methods Dermatology - trends Eczema - drug therapy Eczema - immunology Humans Immunopathology Medical sciences Skin allergic diseases. Stinging insect allergies |
| title | Changing paradigms in dermatology: topical immunomodulators within a permutational paradigm for the treatment of atopic and eczematous dermatitis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T17%3A31%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changing%20paradigms%20in%20dermatology:%20topical%20immunomodulators%20within%20a%20permutational%20paradigm%20for%20the%20treatment%20of%20atopic%20and%20eczematous%20dermatitis&rft.jtitle=Clinics%20in%20dermatology&rft.au=Abramovits,%20William&rft.date=2003-09-01&rft.volume=21&rft.issue=5&rft.spage=383&rft.epage=391&rft.pages=383-391&rft.issn=0738-081X&rft.eissn=1879-1131&rft_id=info:doi/10.1016/j.clindermatol.2003.08.013&rft_dat=%3Cproquest_cross%3E71469902%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c472t-b1be8dfd33e3eed5e1acf81d289943a80d3780a8a1b283d0aea8a0c97d0728db3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71469902&rft_id=info:pmid/14678718&rfr_iscdi=true |